Life Biosciences raised a fully subscribed $80 million Series D to advance ER-100 in phase I trials, targeting biological aging through partial epigenetic reprogramming. The capital funds operations into the second half of 2027 and supports the company’s progression through early clinical milestones. The financing reflects continued investor appetite for longevity-adjacent therapeutic approaches moving from research into first-in-human testing.